Medicina (Feb 2023)

Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells

  • Mahsa Naghashpour,
  • Dian Dayer,
  • Hadi Karami,
  • Mahshid Naghashpour,
  • Mahin Taheri Moghadam,
  • Seyed Mohammad Jafar Haeri,
  • Katsuhiko Suzuki

DOI
https://doi.org/10.3390/medicina59020286
Journal volume & issue
Vol. 59, no. 2
p. 286

Abstract

Read online

Background and Objectives: Combination therapy improves the effect of chemotherapy on tumor cells. Magnolol, used in treating gastrointestinal disorders, has been shown to have anti-cancer properties. We investigated the synergistic effect of cisplatin and magnolol on the viability and maintenance of MKN-45 gastric cancer cells. Materials and Methods: The toxicity of magnolol and/or cisplatin was determined using the MTT technique. The trypan blue method was used to test magnolol and/or cisplatin’s effect on MKN-45 cell growth. Crystal violet staining was used to assess the treated cells’ tendency for colony formation. The expression of genes linked to apoptosis, cell cycle arrest, and cell migration was examined using the qPCR method. Results: According to MTT data, using magnolol and/or cisplatin significantly reduced cell viability. The ability of the treated cells to proliferate and form colonies was also reduced considerably. Magnolol and/or cisplatin treatment resulted in a considerable elevation in Bax expression. However, the level of Bcl2 expression was dramatically reduced. p21 and p53 expression levels were significantly increased in the treated cells, while MMP-9 expression was significantly reduced. Conclusions: These findings show that magnolol has a remarkable anti-tumor effect on MKN-45 cells. In combination with cisplatin, magnolol may be utilized to overcome cisplatin resistance in gastric cancer cells.

Keywords